메뉴 건너뛰기




Volumn 12, Issue 6, 2011, Pages 594-603

KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CETUXIMAB; DUAL SPECIFICITY PHOSPHATASE; DUAL SPECIFICITY PHOSPHATASE 4; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; UNCLASSIFIED DRUG;

EID: 79957523828     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70209-6     Document Type: Review
Times cited : (526)

References (79)
  • 1
    • 40849147041 scopus 로고    scopus 로고
    • EGFR antagonists in cancer treatment
    • Ciardiello F, Tortora G EGFR antagonists in cancer treatment. N Engl J Med 2008, 358:1160-1174.
    • (2008) N Engl J Med , vol.358 , pp. 1160-1174
    • Ciardiello, F.1    Tortora, G.2
  • 2
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    • Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
    • (2004) N Engl J Med , vol.350 , pp. 2335-2342
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny, W.3
  • 3
    • 53249123419 scopus 로고    scopus 로고
    • Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study
    • Personeni N, Fieuws S, Piessevaux H, et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res 2008, 14:5869-5876.
    • (2008) Clin Cancer Res , vol.14 , pp. 5869-5876
    • Personeni, N.1    Fieuws, S.2    Piessevaux, H.3
  • 4
    • 73349094741 scopus 로고    scopus 로고
    • Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer
    • Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009, 27:5924-5930.
    • (2009) J Clin Oncol , vol.27 , pp. 5924-5930
    • Laurent-Puig, P.1    Cayre, A.2    Manceau, G.3
  • 5
    • 17844362179 scopus 로고    scopus 로고
    • Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
    • Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005, 6:279-286.
    • (2005) Lancet Oncol , vol.6 , pp. 279-286
    • Moroni, M.1    Veronese, S.2    Benvenuti, S.3
  • 6
    • 34548258303 scopus 로고    scopus 로고
    • Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab
    • Sartore-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007, 25:3238-3245.
    • (2007) J Clin Oncol , vol.25 , pp. 3238-3245
    • Sartore-Bianchi, A.1    Moroni, M.2    Veronese, S.3
  • 7
    • 73349098041 scopus 로고    scopus 로고
    • Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab
    • Jacobs B, De Roock W, Piessevaux H, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2009, 27:5068-5074.
    • (2009) J Clin Oncol , vol.27 , pp. 5068-5074
    • Jacobs, B.1    De Roock, W.2    Piessevaux, H.3
  • 8
    • 77949887855 scopus 로고    scopus 로고
    • Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study
    • Tabernero J, Cervantes A, Rivera F, et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J Clin Oncol 2010, 28:1181-1189.
    • (2010) J Clin Oncol , vol.28 , pp. 1181-1189
    • Tabernero, J.1    Cervantes, A.2    Rivera, F.3
  • 9
    • 34548238762 scopus 로고    scopus 로고
    • Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
    • Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007, 25:3230-3237.
    • (2007) J Clin Oncol , vol.25 , pp. 3230-3237
    • Khambata-Ford, S.1    Garrett, C.R.2    Meropol, N.J.3
  • 10
    • 77955604846 scopus 로고    scopus 로고
    • Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer
    • Perkins G, Lièvre A, Ramacci C, et al. Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer. Int J Cancer 2010, 127:1321-1331.
    • (2010) Int J Cancer , vol.127 , pp. 1321-1331
    • Perkins, G.1    Lièvre, A.2    Ramacci, C.3
  • 11
    • 65349189958 scopus 로고    scopus 로고
    • American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy
    • Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009, 27:2091-2096.
    • (2009) J Clin Oncol , vol.27 , pp. 2091-2096
    • Allegra, C.J.1    Jessup, J.M.2    Somerfield, M.R.3
  • 12
    • 77955277111 scopus 로고    scopus 로고
    • Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
    • De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11:753-762.
    • (2010) Lancet Oncol , vol.11 , pp. 753-762
    • De Roock, W.1    Claes, B.2    Bernasconi, D.3
  • 13
    • 57449095367 scopus 로고    scopus 로고
    • BRAF wild-type is required for response to panitumumab or cetuximab in metastatic colorectal cancer
    • Di Nicolantonio F, Martini M, Molinari F, et al. BRAF wild-type is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26:5705-5712.
    • (2008) J Clin Oncol , vol.26 , pp. 5705-5712
    • Di Nicolantonio, F.1    Martini, M.2    Molinari, F.3
  • 14
    • 77955266489 scopus 로고    scopus 로고
    • Cetuximab plus FOLFIRI: final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome
    • abstr 3570.
    • Van Cutsem E, Lang I, Folprecht G, et al. Cetuximab plus FOLFIRI: final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome. Proc Am Soc Clin Oncol 2010, 28. abstr 3570.
    • (2010) Proc Am Soc Clin Oncol , vol.28
    • Van Cutsem, E.1    Lang, I.2    Folprecht, G.3
  • 15
    • 62449302407 scopus 로고    scopus 로고
    • PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies
    • Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009, 69:1851-1857.
    • (2009) Cancer Res , vol.69 , pp. 1851-1857
    • Sartore-Bianchi, A.1    Martini, M.2    Molinari, F.3
  • 16
    • 65649086786 scopus 로고    scopus 로고
    • PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer
    • Prenen H, De Schutter J, Jacobs B, et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009, 15:3184-3188.
    • (2009) Clin Cancer Res , vol.15 , pp. 3184-3188
    • Prenen, H.1    De Schutter, J.2    Jacobs, B.3
  • 17
    • 35348908314 scopus 로고    scopus 로고
    • PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
    • Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007, 97:1139-1145.
    • (2007) Br J Cancer , vol.97 , pp. 1139-1145
    • Frattini, M.1    Saletti, P.2    Romagnani, E.3
  • 18
    • 66849140563 scopus 로고    scopus 로고
    • PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer
    • Loupakis F, Pollina L, Stasi I, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009, 27:2622-2629.
    • (2009) J Clin Oncol , vol.27 , pp. 2622-2629
    • Loupakis, F.1    Pollina, L.2    Stasi, I.3
  • 19
    • 77949435827 scopus 로고    scopus 로고
    • Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer
    • Bardelli A, Siena S Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010, 28:1254-1261.
    • (2010) J Clin Oncol , vol.28 , pp. 1254-1261
    • Bardelli, A.1    Siena, S.2
  • 20
    • 0028074316 scopus 로고
    • Phosphatidylinositol-3-OH kinase as a direct target of Ras
    • Rodriguez-Viciana P, Warne PH, Dhand R, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994, 370:527-532.
    • (1994) Nature , vol.370 , pp. 527-532
    • Rodriguez-Viciana, P.1    Warne, P.H.2    Dhand, R.3
  • 21
    • 58249089525 scopus 로고    scopus 로고
    • CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer
    • Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009, 58:90-96.
    • (2009) Gut , vol.58 , pp. 90-96
    • Ogino, S.1    Nosho, K.2    Kirkner, G.J.3
  • 23
    • 33646228635 scopus 로고    scopus 로고
    • KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
    • Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66:3992-3995.
    • (2006) Cancer Res , vol.66 , pp. 3992-3995
    • Lièvre, A.1    Bachet, J.B.2    Le Corre, D.3
  • 24
    • 78049341541 scopus 로고    scopus 로고
    • Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
    • De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010, 304:1812-1820.
    • (2010) JAMA , vol.304 , pp. 1812-1820
    • De Roock, W.1    Jonker, D.J.2    Di Nicolantonio, F.3
  • 25
    • 63149194964 scopus 로고    scopus 로고
    • V600E BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
    • Pratilas CA, Taylor BS, Yeb Q, et al. V600E BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci USA 2009, 106:4519-4524.
    • (2009) Proc Natl Acad Sci USA , vol.106 , pp. 4519-4524
    • Pratilas, C.A.1    Taylor, B.S.2    Yeb, Q.3
  • 26
    • 79957488015 scopus 로고    scopus 로고
    • DUSP expression as a predictor of outcome after cetuximab treatment in Kras wild-type and mutant colorectal tumors. Gastrointestinal Cancer Symposium of the American Society of Clinical Oncology; San Francisco, CA, USA; Jan 22-24, 2010. Abstract 289.
    • De Roock W, Fieuws S, Biesmans B, et al. DUSP expression as a predictor of outcome after cetuximab treatment in Kras wild-type and mutant colorectal tumors. Gastrointestinal Cancer Symposium of the American Society of Clinical Oncology; San Francisco, CA, USA; Jan 22-24, 2010. Abstract 289.
    • De Roock, W.1    Fieuws, S.2    Biesmans, B.3
  • 27
    • 22244472992 scopus 로고    scopus 로고
    • Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers
    • Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005, 65:6063-6069.
    • (2005) Cancer Res , vol.65 , pp. 6063-6069
    • Samowitz, W.S.1    Sweeney, C.2    Herrick, J.3
  • 28
    • 75749102647 scopus 로고    scopus 로고
    • Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial
    • Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010, 28:466-474.
    • (2010) J Clin Oncol , vol.28 , pp. 466-474
    • Roth, A.D.1    Tejpar, S.2    Delorenzi, M.3
  • 29
    • 79957459729 scopus 로고    scopus 로고
    • Use of massively parallel, next-generation sequencing to identify gene mutations beyond KRAS that predict response to panitumumab in a randomized phase III monotherapy study of metastatic colorectal cancer. American Association for Cancer Research Annual Meeting; Washington, DC, USA; April 17-21, 2010. Abstract 174.
    • Peeters M, Oliner KS, Parker A, et al. Use of massively parallel, next-generation sequencing to identify gene mutations beyond KRAS that predict response to panitumumab in a randomized phase III monotherapy study of metastatic colorectal cancer. American Association for Cancer Research Annual Meeting; Washington, DC, USA; April 17-21, 2010. Abstract 174.
    • Peeters, M.1    Oliner, K.S.2    Parker, A.3
  • 30
    • 77951945506 scopus 로고    scopus 로고
    • Status of PI3K inhibition and biomarker development in cancer therapeutics
    • Markman B, Atzori F, Perez-Garci{dotless}a J, Tabernero J, Baselga J Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol 2010, 21:683-691.
    • (2010) Ann Oncol , vol.21 , pp. 683-691
    • Markman, B.1    Atzori, F.2    Perez-Garcia, J.3    Tabernero, J.4    Baselga, J.5
  • 31
    • 44449133319 scopus 로고    scopus 로고
    • PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations
    • Nosho K, Kawasaki T, Ohnishi M, et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 2008, 10:534-541.
    • (2008) Neoplasia , vol.10 , pp. 534-541
    • Nosho, K.1    Kawasaki, T.2    Ohnishi, M.3
  • 32
    • 42149083899 scopus 로고    scopus 로고
    • Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signalling network correlate with poor survival in a population-based series of colon cancers
    • Barault L, Veyrie N, Jooste V, et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signalling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 2008, 122:2255-2259.
    • (2008) Int J Cancer , vol.122 , pp. 2255-2259
    • Barault, L.1    Veyrie, N.2    Jooste, V.3
  • 33
    • 70350028742 scopus 로고    scopus 로고
    • Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer
    • Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009, 4:7287.
    • (2009) PLoS One , vol.4 , pp. 7287
    • Sartore-Bianchi, A.1    Di Nicolantonio, F.2    Nichelatti, M.3
  • 34
    • 40649096375 scopus 로고    scopus 로고
    • Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms
    • Zhao L, Vogt PK Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA 2008, 105:2652-2657.
    • (2008) Proc Natl Acad Sci USA , vol.105 , pp. 2652-2657
    • Zhao, L.1    Vogt, P.K.2
  • 35
    • 63049111794 scopus 로고    scopus 로고
    • PIK3CA mutation Is associated with poor prognosis among patients with curatively resected colon cancer
    • Ogino S, Katsuhiko N, Gregory J, et al. PIK3CA mutation Is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 2009, 27:1477-1484.
    • (2009) J Clin Oncol , vol.27 , pp. 1477-1484
    • Ogino, S.1    Katsuhiko, N.2    Gregory, J.3
  • 36
    • 35148885729 scopus 로고    scopus 로고
    • A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
    • Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
    • (2007) Cancer Cell , vol.12 , pp. 395-402
    • Berns, K.1    Horlings, H.M.2    Hennessy, B.T.3
  • 37
    • 2342504508 scopus 로고    scopus 로고
    • Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers
    • Goel A, Arnold CN, Niedzwiecki D, et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res 2004, 64:3014-3021.
    • (2004) Cancer Res , vol.64 , pp. 3014-3021
    • Goel, A.1    Arnold, C.N.2    Niedzwiecki, D.3
  • 38
    • 5144226211 scopus 로고    scopus 로고
    • PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
    • Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
    • (2004) Cancer Cell , vol.6 , pp. 117-127
    • Nagata, Y.1    Lan, K.H.2    Zhou, X.3
  • 39
    • 68949201629 scopus 로고    scopus 로고
    • Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
    • Gazdar AF Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009, 28:24.
    • (2009) Oncogene , vol.28 , pp. 24
    • Gazdar, A.F.1
  • 41
    • 25144476901 scopus 로고    scopus 로고
    • Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer
    • Ogino S, Meyerhardt JA, Cantor M, et al. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res 2005, 11:6650-6656.
    • (2005) Clin Cancer Res , vol.11 , pp. 6650-6656
    • Ogino, S.1    Meyerhardt, J.A.2    Cantor, M.3
  • 42
    • 70350653741 scopus 로고    scopus 로고
    • Nuclear EGFR contributes to acquired resistance to cetuximab
    • Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 2009, 28:3801-3813.
    • (2009) Oncogene , vol.28 , pp. 3801-3813
    • Li, C.1    Iida, M.2    Dunn, E.F.3    Ghia, A.J.4    Wheeler, D.L.5
  • 43
    • 34250898667 scopus 로고    scopus 로고
    • Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt
    • Yamasaki F, Johansen MJ, Zhang D, et al. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res 2007, 67:5779-5788.
    • (2007) Cancer Res , vol.67 , pp. 5779-5788
    • Yamasaki, F.1    Johansen, M.J.2    Zhang, D.3
  • 44
    • 19944427176 scopus 로고    scopus 로고
    • Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells
    • Jones HE, Goddard L, Gee JM, et al. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004, 11:793-814.
    • (2004) Endocr Relat Cancer , vol.11 , pp. 793-814
    • Jones, H.E.1    Goddard, L.2    Gee, J.M.3
  • 45
    • 0037110602 scopus 로고    scopus 로고
    • Overexpression of the insulin-like growth factor I receptor in human colon carcinomas
    • Weber MM, Fottner C, Liu SB, Jung MC, Engelhardt D, Baretton GB Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer 2002, 95:2086-2095.
    • (2002) Cancer , vol.95 , pp. 2086-2095
    • Weber, M.M.1    Fottner, C.2    Liu, S.B.3    Jung, M.C.4    Engelhardt, D.5    Baretton, G.B.6
  • 46
    • 54249155585 scopus 로고    scopus 로고
    • Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor
    • Hu YP, Patil SB, Panasiewicz M, et al. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor. Cancer Res 2008, 68:8004-8013.
    • (2008) Cancer Res , vol.68 , pp. 8004-8013
    • Hu, Y.P.1    Patil, S.B.2    Panasiewicz, M.3
  • 47
    • 77955856575 scopus 로고    scopus 로고
    • Correlation of insulin-like growth factor 1 (IGF-1) expression and clinical outcome in K-RAS wild-type colorectal cancer patients treated with cetuximab-irinotecan
    • abstr 4017.
    • Scartozzi M, Bearzi I, Mandolesi A, et al. Correlation of insulin-like growth factor 1 (IGF-1) expression and clinical outcome in K-RAS wild-type colorectal cancer patients treated with cetuximab-irinotecan. Proc Am Soc Clin Oncol 2009, 27. abstr 4017.
    • (2009) Proc Am Soc Clin Oncol , vol.27
    • Scartozzi, M.1    Bearzi, I.2    Mandolesi, A.3
  • 48
    • 34249075147 scopus 로고    scopus 로고
    • MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
    • Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
    • (2007) Science , vol.316 , pp. 1039-1043
    • Engelman, J.A.1    Zejnullahu, K.2    Mitsudomi, T.3
  • 49
    • 56449089812 scopus 로고    scopus 로고
    • Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations
    • Yano S, Wang W, Li Q, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008, 68:9479-9487.
    • (2008) Cancer Res , vol.68 , pp. 9479-9487
    • Yano, S.1    Wang, W.2    Li, Q.3
  • 50
    • 0037386758 scopus 로고    scopus 로고
    • C-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases
    • Takeuchi H, Bilchik A, Saha S, et al. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res 2003, 9:1480-1488.
    • (2003) Clin Cancer Res , vol.9 , pp. 1480-1488
    • Takeuchi, H.1    Bilchik, A.2    Saha, S.3
  • 51
    • 52449122415 scopus 로고    scopus 로고
    • The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer
    • Ginty F, Adak S, Can A, et al. The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer. Clin Cancer Res 2008, 14:3814-3822.
    • (2008) Clin Cancer Res , vol.14 , pp. 3814-3822
    • Ginty, F.1    Adak, S.2    Can, A.3
  • 52
    • 33847326735 scopus 로고    scopus 로고
    • Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome
    • Kammula US, Kuntz EJ, Francone TD, et al. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett 2007, 248:219-228.
    • (2007) Cancer Lett , vol.248 , pp. 219-228
    • Kammula, U.S.1    Kuntz, E.J.2    Francone, T.D.3
  • 53
    • 0037358220 scopus 로고    scopus 로고
    • Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo
    • Long IS, Han K, Li M, et al. Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo. Mol Cancer Res 2003, 1:393-401.
    • (2003) Mol Cancer Res , vol.1 , pp. 393-401
    • Long, I.S.1    Han, K.2    Li, M.3
  • 54
    • 0037105707 scopus 로고    scopus 로고
    • Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer
    • Boon EM, van der Neut R, van de Wetering M, Clevers H, Pals ST Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res 2002, 62:5126-5128.
    • (2002) Cancer Res , vol.62 , pp. 5126-5128
    • Boon, E.M.1    van der Neut, R.2    van de Wetering, M.3    Clevers, H.4    Pals, S.T.5
  • 55
    • 0037905558 scopus 로고    scopus 로고
    • Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells
    • Herynk MH, Stoeltzing O, Reinmuth N, et al. Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells. Cancer Res 2003, 63:2990-2996.
    • (2003) Cancer Res , vol.63 , pp. 2990-2996
    • Herynk, M.H.1    Stoeltzing, O.2    Reinmuth, N.3
  • 56
    • 0036251746 scopus 로고    scopus 로고
    • Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery
    • Lee JC, Wang ST, Chow NH, Yang HB Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 2002, 38:1065-1071.
    • (2002) Eur J Cancer , vol.38 , pp. 1065-1071
    • Lee, J.C.1    Wang, S.T.2    Chow, N.H.3    Yang, H.B.4
  • 57
    • 0037012008 scopus 로고    scopus 로고
    • Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells
    • Venkateswarlu S, Dawson DM, St Clair P, Gupta A, Willson JK, Brattain MG Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells. Oncogene 2002, 21:78-86.
    • (2002) Oncogene , vol.21 , pp. 78-86
    • Venkateswarlu, S.1    Dawson, D.M.2    St Clair, P.3    Gupta, A.4    Willson, J.K.5    Brattain, M.G.6
  • 58
    • 79957508906 scopus 로고    scopus 로고
    • Heregulin as a novel resistant factor for cetuximab. American Association for Cancer Research 101st Annual Meeting; Washington, DC, USA; April 17-21, 2010. Abstract 3733.
    • Yonesaka K, Okamoto I, Satoh T, et al. Heregulin as a novel resistant factor for cetuximab. American Association for Cancer Research 101st Annual Meeting; Washington, DC, USA; April 17-21, 2010. Abstract 3733.
    • Yonesaka, K.1    Okamoto, I.2    Satoh, T.3
  • 59
    • 52649143725 scopus 로고    scopus 로고
    • Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells
    • Bianco R, Rosa R, Damiano V, et al. Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. Clin Cancer Res 2008, 14:5069-5080.
    • (2008) Clin Cancer Res , vol.14 , pp. 5069-5080
    • Bianco, R.1    Rosa, R.2    Damiano, V.3
  • 60
    • 47549092230 scopus 로고    scopus 로고
    • Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions
    • Barr S, Thomson S, Buck E, et al. Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin Exp Metastasis 2008, 25:685-693.
    • (2008) Clin Exp Metastasis , vol.25 , pp. 685-693
    • Barr, S.1    Thomson, S.2    Buck, E.3
  • 61
    • 57049132745 scopus 로고    scopus 로고
    • Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy
    • Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis 2008, 25:843-854.
    • (2008) Clin Exp Metastasis , vol.25 , pp. 843-854
    • Thomson, S.1    Petti, F.2    Sujka-Kwok, I.3    Epstein, D.4    Haley, J.D.5
  • 62
    • 0141838134 scopus 로고    scopus 로고
    • Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids
    • Bates RC, Goldsmith JD, Bachelder RE, et al. Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids. Curr Biol 2003, 13:1721-1727.
    • (2003) Curr Biol , vol.13 , pp. 1721-1727
    • Bates, R.C.1    Goldsmith, J.D.2    Bachelder, R.E.3
  • 63
    • 29344465338 scopus 로고    scopus 로고
    • Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients
    • Yauch RL, Januario T, Eberhard DA, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005, 11:8686-8698.
    • (2005) Clin Cancer Res , vol.11 , pp. 8686-8698
    • Yauch, R.L.1    Januario, T.2    Eberhard, D.A.3
  • 64
    • 0034735754 scopus 로고    scopus 로고
    • Simultaneous blockage of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts
    • De Luca A, Arra C, D'Antonio A, et al. Simultaneous blockage of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts. Oncogene 2000, 19:5863-5871.
    • (2000) Oncogene , vol.19 , pp. 5863-5871
    • De Luca, A.1    Arra, C.2    D'Antonio, A.3
  • 65
    • 68949086867 scopus 로고    scopus 로고
    • Targeting the RAF-MEK-ERK pathway in cancer therapy
    • Montagut C, Settleman J Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 2009, 283:125-134.
    • (2009) Cancer Lett , vol.283 , pp. 125-134
    • Montagut, C.1    Settleman, J.2
  • 66
    • 31144453233 scopus 로고    scopus 로고
    • BRAF mutation predicts sensitivity to MEK inhibition
    • Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
    • (2006) Nature , vol.439 , pp. 358-362
    • Solit, D.B.1    Garraway, L.A.2    Pratilas, C.A.3
  • 67
    • 42649125571 scopus 로고    scopus 로고
    • Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon
    • Haigis KM, Kendall KR, Wang Y, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008, 40:600-608.
    • (2008) Nat Genet , vol.40 , pp. 600-608
    • Haigis, K.M.1    Kendall, K.R.2    Wang, Y.3
  • 68
    • 42949149240 scopus 로고    scopus 로고
    • Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
    • Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008, 105:3041-3046.
    • (2008) Proc Natl Acad Sci USA , vol.105 , pp. 3041-3046
    • Tsai, J.1    Lee, J.T.2    Wang, W.3
  • 69
    • 78649723255 scopus 로고    scopus 로고
    • PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors
    • abstr 3534.
    • Kopetz S, Desai J, Chan E, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. Proc Am Soc Clin Oncol 2010, 28. abstr 3534.
    • (2010) Proc Am Soc Clin Oncol , vol.28
    • Kopetz, S.1    Desai, J.2    Chan, E.3
  • 70
    • 66149126085 scopus 로고    scopus 로고
    • Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression
    • Hoeflich KP, Herter S, Tien J, et al. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res 2009, 69:3042-3051.
    • (2009) Cancer Res , vol.69 , pp. 3042-3051
    • Hoeflich, K.P.1    Herter, S.2    Tien, J.3
  • 71
    • 77949685981 scopus 로고    scopus 로고
    • RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
    • Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464:431-435.
    • (2010) Nature , vol.464 , pp. 431-435
    • Hatzivassiliou, G.1    Song, K.2    Yen, I.3
  • 72
    • 33749430399 scopus 로고    scopus 로고
    • Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner
    • Skeen JE, Bhaskar PT, Chen C-C Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell 2006, 10:269-280.
    • (2006) Cancer Cell , vol.10 , pp. 269-280
    • Skeen, J.E.1    Bhaskar, P.T.2    Chen, C.-C.3
  • 73
    • 32944457518 scopus 로고    scopus 로고
    • MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
    • O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508.
    • (2006) Cancer Res , vol.66 , pp. 1500-1508
    • O'Reilly, K.E.1    Rojo, F.2    She, Q.B.3
  • 74
    • 66249116702 scopus 로고    scopus 로고
    • PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers
    • Wee S, Jagani Z, Xiang KX, et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009, 69:4286-4293.
    • (2009) Cancer Res , vol.69 , pp. 4286-4293
    • Wee, S.1    Jagani, Z.2    Xiang, K.X.3
  • 75
    • 51349164790 scopus 로고    scopus 로고
    • Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
    • Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008, 118:3065-3074.
    • (2008) J Clin Invest , vol.118 , pp. 3065-3074
    • Carracedo, A.1    Ma, L.2    Teruya-Feldstein, J.3
  • 76
    • 63349097231 scopus 로고    scopus 로고
    • Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer
    • Zhang YJ, Tian XQ, Sun DF, Zhao SL, Xiong H, Fang JY Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer. Cancer Invest 2009, 27:273-285.
    • (2009) Cancer Invest , vol.27 , pp. 273-285
    • Zhang, Y.J.1    Tian, X.Q.2    Sun, D.F.3    Zhao, S.L.4    Xiong, H.5    Fang, J.Y.6
  • 77
    • 57349194139 scopus 로고    scopus 로고
    • Effective use of PI3K and MEK inhibitors to treat mutant KRAS G12D and PIK3CA H1047R murine lung cancers
    • Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant KRAS G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008, 14:1351-1356.
    • (2008) Nat Med , vol.14 , pp. 1351-1356
    • Engelman, J.A.1    Chen, L.2    Tan, X.3
  • 78
    • 58349091262 scopus 로고    scopus 로고
    • Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition
    • Mirzoeva OK, Das D, Heiser LM, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 2009, 69:565-572.
    • (2009) Cancer Res , vol.69 , pp. 565-572
    • Mirzoeva, O.K.1    Das, D.2    Heiser, L.M.3
  • 79
    • 77955288855 scopus 로고    scopus 로고
    • Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
    • Di Nicolantonio F, Arena S, Tabernero J, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 2010, 120:2858-2866.
    • (2010) J Clin Invest , vol.120 , pp. 2858-2866
    • Di Nicolantonio, F.1    Arena, S.2    Tabernero, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.